arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Edwards Lifesciences Corp

EW
$100.81 ▲ +1.55 (+1.57%) at close
Healthcare ·Orthopedic, Prosthetic & Surgical Appliances & Supplies ·USOrthopedic, Prosthetic & Surgical Appliances & Supplies
19 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Edwards Lifesciences Corp shows strong fundamentals with top-quartile Profit Margin (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $59.0B
Dividend Yield —
Revenue Growth 11.5% ↗
Op. Margin 20.8% ↘
ROIC 9.6% ↘
FCF / Share $2.28 ↗
Trailing P/E 54.8x
Price / Book 5.7x
FCF Yield 2.3%
Debt / Equity 0.06
info Valuation on last close. End-of-day price, Nov 5, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$6.07B
↑ +11.5% —
Net Income Profit after all expenses
$1.07B
↓ -74.3% —
Operating Margin Operating profit as % of sales
20.8%
↓ -17.8% 77th
FCF / Share Free cash flow per share
$2.28
↑ +370.7% —
Long-Term Debt Long-term obligations
$598.30M
— +0.1% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↓
80
Returns ↓
69
Financial Health ↓
90
Cash Quality ↑
74

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 19 years · 72 quarters